Development-associated immunophenotypes reveal the heterogeneous and individualized early responses of adult B-acute lymphoblastic leukemia. Issue 34 (August 2016)

• Record Type: Journal Article
• Authors: Li, Hui-Fang; Meng, Wen-Tong; Jia, Yong-Qian; Jiang, Neng-Gang; Zeng, Ting-Ting; Jin, Yong-Mei; Huang, Qiao-Rong; Li, Xue; Xu, Hong; Mo, Xian-Ming
• Other Names: Liu. Yong section editor.
• Is Part Of: Medicine. Volume 95:Issue 34(2016)
• Publication Date: 2016-08
• Subjects: adult B-acute lymphoblastic leukemia -- early responses -- leukemia cell subpopulations -- multicolor flow cytometry; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000004128
• Languages: English
• ISSNs: 0025-7974

Abstract

Abstract : Abstract: B cell acute lymphoblastic leukemia (B-ALL) exhibits phenotypes reminiscent of normal stages of B-cell development. As demonstrated by flow cytometry, the immunophenotypes are able to determine the stages of B cell development. Multicolor flow cytometry (MFC) is more accurate at identifying cell populations. In this study, 9-color panels, including CD10, CD19, CD20, CD22, CD34, CD79a, CD179a, and IgM, which are sequentially expressed during B cell development, were designed to detect the leukemia cell subpopulations in adult B-ALL patients. In 23 patients at diagnosis, 192 heterogeneous subpopulations of leukemia cells were detected. Compared with their counterparts at diagnosis and after the 1st course of induction therapy, the responses of the subpopulations were also heterogeneous. In the CD10 + population, the residual B cell subpopulations in the BCR/ABL + patients were obviously reduced compared to those in the BCR/ABL − patients. New subpopulations were detected in 22 of 23 patients and were primarily located in the CD34 + CD10 − populations. Subpopulations of clonal evolution were heterogeneous after induction therapy. Our results suggest that the subpopulations in B-ALL patients should be dynamically monitored by development-associated immunophenotyping before, during, and after induction therapy and to predict the prognosis of the disease. Abstract : Supplemental Digital Content is available in the text